Company
Century Therapeutics
- Biotech
Description
Develops off-the-shelf cell therapy candidates from induced pluripotent stem cells for patients with autoimmune conditions, including type 1 diabetes, and cancer.
Related
HexemBioBuilds rejuvenated stem cell therapy aimed at improving aged hematopoietic stem cells and bone marrow transplant outcomes for blood cancer…
Sana Biotechnology ($SANA)Builds engineered cell medicines that repair or control genes, or replace damaged cells, for patients with diseases including diabetes,…
Kyverna Therapeutics (San Diego)Develops cell therapies for autoimmune disease patients, including an autologous CD19-targeting CAR T candidate being studied in ongoing…
Artiva Biotherapeutics ($ARTV)Develops off-the-shelf, non-genetically modified natural killer cell therapies for deep B-cell depletion, aiming to help patients with…
Cartesian Therapeutics ($RNAC)Develops clinical-stage mRNA cell therapies designed to treat autoimmune diseases, aiming to expand access to cell therapy for patients…
Boundless Bio ($BOLD)Develops ecDNA-directed cancer therapies that target vulnerabilities in cancer cells for patients with intractable oncogene-amplified…
Poseida Therapeutics (Roche)Develops cell therapy candidates and related platform technologies, with legacy programs in a biotechnology pipeline for medicines…
CellaresDevelops and operates automated cell therapy manufacturing technologies and services, helping therapy developers transfer production and…
Cabaletta Bio ($CABA)Develops engineered T cell therapies for autoimmune diseases, including rese-cel in Phase 1/2 trials for lupus, myositis, systemic…
CRISPR Therapeutics ($CRSP)CRISPR Therapeutics develops CRISPR-based gene-editing therapies across hemoglobinopathies, oncology, diabetes, and cardiovascular disease,…
Humacyte ($HUMA)Develops and manufactures bioengineered human tissues and organs intended as off-the-shelf regenerative implants, with investigational…
Legend Biotech ($LEGN)CAR-T cell therapy company behind ciltacabtagene autoleucel and next-generation cell-therapy programs. Public via $LEGN (NASDAQ).